$350 Million is the total value of Tamarack Advisers, LP's 32 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVA | Buy | NUVASIVE INCequity | $37,412,000 | +43.6% | 525,000 | +5.0% | 10.68% | +22.5% |
| Sell | NOVOCURE LTDequity | $33,414,000 | -3.0% | 635,000 | -42.3% | 9.54% | -17.2% | |
| LH | Buy | LABORATORY CRP OF AMER HLDGSequity | $27,789,000 | +50.3% | 160,000 | +55.3% | 7.94% | +28.2% |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $26,442,000 | +37.7% | 1,950,000 | +21.9% | 7.55% | +17.5% |
| MDT | Sell | MEDTRONIC PLCequity | $25,576,000 | -7.8% | 260,000 | -19.8% | 7.30% | -21.3% |
| SRCL | Buy | STERICYCLE INCequity | $21,712,000 | +33.0% | 370,000 | +48.0% | 6.20% | +13.5% |
| BIO | Buy | BIO-RAD LABORATORIES-Aequity | $20,344,000 | +28.2% | 65,000 | +18.2% | 5.81% | +9.4% |
| NXTM | Buy | NXSTAGE MEDICAL INCequity | $16,734,000 | +27.5% | 600,000 | +27.5% | 4.78% | +8.7% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INCequity | $14,606,000 | +96.6% | 4,550,000 | +73.3% | 4.17% | +67.7% |
| LNTH | Buy | LANTHEUS HOLDINGS INCequity | $14,502,000 | +27.0% | 970,000 | +23.6% | 4.14% | +8.4% |
| HOLX | Buy | HOLOGIC INCequity | $14,343,000 | +106.2% | 350,000 | +100.0% | 4.10% | +75.9% |
| CORI | Buy | CORIUM INTERNATIONAL INCequity | $13,552,000 | +24.0% | 1,425,000 | +4.5% | 3.87% | +5.8% |
| GILD | Sell | GILEAD SCIENCES INCequity | $13,512,000 | -4.6% | 175,000 | -12.5% | 3.86% | -18.7% |
| OPTN | Buy | OPTINOSE INCequity | $10,690,000 | -38.9% | 860,000 | +37.6% | 3.05% | -47.9% |
| ATRC | Buy | ATRICURE INCequity | $9,633,000 | +37.0% | 275,000 | +5.8% | 2.75% | +16.8% |
| SCI | Buy | SERVICE CORP INTERNATIONALequity | $9,452,000 | +36.5% | 213,856 | +10.5% | 2.70% | +16.4% |
| CORV | Buy | CORREVIO PHARMA CORPequity | $8,281,000 | +9.5% | 2,060,000 | +3.0% | 2.36% | -6.6% |
| PCRX | Sell | PACIRA PHARMACEUTICALS INCequity | $7,373,000 | +21.1% | 150,000 | -21.1% | 2.10% | +3.2% |
| VSI | Sell | VITAMIN SHOPPE INCequity | $6,000,000 | -6.7% | 600,000 | -35.1% | 1.71% | -20.4% |
| OBLN | Buy | OBALON THERAPEUTICS INCequity | $5,670,000 | +151.1% | 2,100,000 | +100.0% | 1.62% | +114.2% |
| GKOS | New | GLAUKOS CORPequity | $4,868,000 | – | 75,000 | +100.0% | 1.39% | – |
| OPHT | Buy | OPHTHOTECH CORPequity | $2,360,000 | -6.5% | 1,000,000 | +8.1% | 0.67% | -20.2% |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONSequity | $2,242,000 | +35.6% | 1,900,000 | +62.1% | 0.64% | +15.7% |
| MODN | New | MODEL N INCequity | $1,585,000 | – | 100,000 | +100.0% | 0.45% | – |
| New | ALKS US 12/21/18 C45call | $696,000 | – | 2,000 | +100.0% | 0.20% | – | |
| New | IWM US 10/19/18 P165put | $539,000 | – | 7,000 | +100.0% | 0.15% | – | |
| New | GILD US 01/18/19 C85call | $340,000 | – | 2,500 | +100.0% | 0.10% | – | |
| Sell | SPY US 10/19/18 P290put | $294,000 | -68.6% | 1,500 | -75.0% | 0.08% | -73.2% | |
| New | AMGN US 01/18/19 P210put | $197,000 | – | 200 | +100.0% | 0.06% | – | |
| New | MDCO US 10/19/18 P25put | $72,000 | – | 2,000 | +100.0% | 0.02% | – | |
| Exit | HSIC US 08/17/18 P75put | $0 | – | -1,000 | -100.0% | -0.14% | – | |
| Exit | PDCO US 08/17/18 P25put | $0 | – | -1,630 | -100.0% | -0.16% | – | |
| LMNX | Exit | LUMINEX CORPequity | $0 | – | -79,089 | -100.0% | -0.78% | – |
| SIEN | Exit | SIENTRA INCequity | $0 | – | -125,000 | -100.0% | -0.82% | – |
| XRAY | Exit | DENTSPLY SIRONA INCequity | $0 | – | -275,000 | -100.0% | -4.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.